Physician profile
Mary E Mazer
NPI 1083982383
$4,437.57
in general payments reported to CMS, 2019-2025
36 companies · $1,913 in 2025
The $1,913 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $469 · 2022: $419 · 2023: $733 · 2024: $903 · 2025: $1,913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,359 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,358.76 |
| Education | $189.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $533.86 | 2021-2025 | Enhertu |
| Astrazeneca Pharmaceuticals Lp | $439.55 | 2021-2025 | Enhertu, Lynparza, Imfinzi |
| Seagen INC. | $431.83 | 2021-2025 | Padcev |
| Gilead Sciences, INC. | $312.78 | 2021-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $272.53 | 2022-2025 | |
| Lilly USA, LLC | $257.51 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Incyte Corporation | $227.53 | 2023-2025 | Jakafi, Niktimvo, Monjuvi |
| Genentech USA, INC. | $224.33 | 2023-2025 | Itovebi, Polivy, Tecentriq |
| Janssen Biotech, INC. | $173.63 | 2025 | Rybrevant, Carvykti, Darzalex |
| Amgen INC. | $158.27 | 2021-2023 | Nplate, Xgeva, Vectibix |
| Puma Biotechnology, INC. | $153.36 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $125.00 | 2022 | |
| Merck Sharp & Dohme LLC | $115.07 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Genentech, INC. | $113.24 | 2025 | Itovebi |
| Aveo Pharmaceuticals, INC. | $85.71 | 2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $84.70 | 2023-2025 | |
| Pfizer INC. | $76.64 | 2025 | |
| Stemline Therapeutics INC. | $62.77 | 2023-2024 | Orserdu |
| Takeda Pharmaceuticals U.S.A., INC. | $57.42 | 2021-2025 | Vpriv |
| Celgene Corporation | $51.71 | 2023-2024 | Reblozyl |
| Genmab U.S., INC. | $49.77 | 2024-2025 | Epkinly |
| Sobi, INC | $45.51 | 2025 | |
| Karyopharm Therapeutics INC. | $43.67 | 2023 | Xpovio |
| Glaxosmithkline, LLC. | $41.60 | 2025 | Blenrep, Zejula, Jemperli |
| Tersera Therapeutics LLC | $39.23 | 2024-2025 | Zoladex |
| Ipsen Biopharmaceuticals, INC | $34.04 | 2024 | Onivyde |
| Regeneron Healthcare Solutions, INC. | $33.71 | 2024-2025 | Libtayo |
| Fresenius Kabi USA, LLC | $27.59 | 2025 | Stimufend |
| Myriad Genetic Laboratories, INC. | $26.86 | 2022 | |
| Legend Biotech USA INC. | $26.45 | 2025 | Carvykti |
| Morphosys, US INC. | $24.74 | 2024 | Monjuvi |
| Spectrum Pharmaceuticals INC. | $23.52 | 2025 | Rolvedon |
| Kyowa Kirin, INC. | $19.02 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.47 | 2023 | |
| Mirati Therapeutics, INC. | $15.00 | 2023 | Krazati |
| Macrogenics, INC. | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Mazer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.